Gilead Sciences Inc Form 4 Filings

At Gilead Sciences, Inc., SVP, Controllership Erin Burkhart converted 2,223 restricted stock units into 2,223 common shares on September 22, 2026. Another 768 shares were delivered or withheld for payment of exercise price or tax liability at $152.67 per share. Her reported post-transaction position included 9,022 restricted stock units. No Rule 10b5-1 plan is reported.

Gilead Sciences, Inc. (GILD) reported that Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock on September 15, 2026 at $145.29 per share in an open-market transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024, and left him holding 164,096 shares directly.

GILEAD SCIENCES, INC. (GILD) reports that Chief Commercial and Corporate Affairs Officer Johanna Mercier sold a total of 3,000 shares of common stock on September 15, 2026 in three open-market or private transactions. These trades were made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025, with sale prices ranging from $143.16 to $144.775 per share for portions of the shares. The filing does not state her remaining holdings.

GILEAD SCIENCES, INC. (GILD) reported that Chief Financial Officer Andrew D. Dickinson exercised restricted stock units for 2,797 shares of common stock on September 10, 2026. The same number of RSUs was converted and removed, and 1,347 shares of common stock were delivered or withheld to cover the exercise price or tax liability, leaving 25,054 restricted stock units directly held. No Rule 10b5-1 trading plan is reported.

Gilead Sciences, Inc. (GILD) reported that Chief Medical Officer Dietmar Berger had restricted stock units vest into 533 shares of common stock on September 10, 2026. Of these, 263 shares were delivered or withheld to cover the exercise price or tax liability, leaving 270 net shares acquired as common stock. The RSU award follows a four-year vesting schedule, and no Rule 10b5-1 trading plan is reported for these transactions.

GILEAD SCIENCES, INC. (GILD) reported that Chief Comm & Corp Aff Officer Johanna Mercier exercised 2,797 restricted stock units into an equal number of shares of common stock on September 10, 2026. Of these, 1,347 shares of common stock were delivered or withheld to pay the exercise price or tax liability, leaving 25,054 restricted stock units reported as remaining. Each restricted stock unit represents the right to receive one share of common stock and follows a 4-year vesting schedule with 25% vesting after one year and 6.25% vesting quarterly thereafter.

GILEAD SCIENCES, INC. (GILD) reported that executive vice president and general counsel Keeley M. Cain Wettan had 590 restricted stock units convert into 590 shares of common stock on September 10, 2026. Of these shares, 285 were delivered or withheld at $144.81 per share to cover the exercise price or tax liability, and Cain Wettan continues to hold 13,405 restricted stock units directly. The units represent the right to receive common shares and follow a four-year vesting schedule with 25% vesting after one year and 6.25% vesting quarterly thereafter, and no Rule 10b5-1 trading plan is reported for these transactions.

GILEAD SCIENCES, INC. (GILD) reported that Chairman & CEO Daniel Patrick O'Day exercised restricted stock units into common stock on September 10, 2026. The transaction involved 8,780 restricted stock units converting into 8,780 shares of common stock, with 4,230 shares delivered or withheld for payment of exercise price or tax liability. Following the derivative transaction, 83,300 restricted stock units remained outstanding, subject to a four-year vesting schedule.

GILEAD SCIENCES, INC. (GILD) reported that Chairman and CEO Daniel Patrick O'Day sold a total of 15,000 shares of common stock on September 1, 2026, in three open-market transactions made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. Sale prices across the trades ranged from $146.94 to $149.94 per share.

GILEAD SCIENCES, INC. (GILD) director Anthony Welters reported an exercise-and-sell transaction on August 26, 2026. He exercised non-qualified stock options covering 18,000 shares of common stock at exercise prices of $60.67 and $61.35 per share, acquiring 18,000 shares. He then sold 18,000 shares of GILD common stock in multiple open-market trades at prices ranging from $147.57 to $149.58 per share, pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.

GILEAD SCIENCES, INC. (GILD) director Jeffrey Bluestone reported option exercises and related share sales. On August 20, 2026 he exercised non-qualified stock options for a total of 5,000 shares of common stock at exercise prices of $67.45 and $61.35 per share, from fully vested grants dating to 2021 and 2022. He then sold the 5,000 resulting common shares in multiple trades at prices between $143.31 and $146.36 per share pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.

GILEAD SCIENCES, INC. (GILD) reported that its Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on 2026-08-17 at $138.36 per share in an open-market or private transaction. After this sale, he directly holds 165,646 shares. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

GILEAD SCIENCES, INC. (GILD) reported insider equity transactions by Chief Commercial and Corporate Affairs Officer Johanna Mercier. On August 17, 2026, she exercised options for 25,000 shares of common stock (23,110 at a $66.64 exercise price and 1,890 at $72.34). She then sold 28,000 shares of common stock in open-market transactions at prices ranging from $136.74 to $138.36 per share. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on February 20, 2025.

Gilead Sciences, Inc. executive Keeley M Cain Wettan, EVP Gen Counsel, Legal & Comp, reported a derivative exercise on restricted stock units. On 2026-08-10, 6,002 restricted stock units converted into 6,002 shares of common stock, and 2,908 common shares at $133.06 per share were delivered or withheld for payment of exercise price or tax liability. Following the transaction, the reporting person held 13,995 restricted stock units directly.

Gilead Sciences chairman and CEO Daniel O'Day reported selling 15,000 shares of common stock on August 3, 2026, in three transactions described as open market or private at reported prices of $129.6583, $130.8022, and $131.3433 per share. The sales were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026, with execution prices in ranges from $129.17 to $130.16, $130.18 to $131.17, and $131.21 to $131.47 per share.

Gilead Sciences Chief Financial Officer Andrew D. Dickinson carried out an open-market sale of 3,000 shares of common stock on July 15, 2026 at an average price of $129.9256 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, and he continues to hold 168,646 shares directly.

Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, reported an open-market sale of 3,000 shares of common stock on 2026-07-15 at a reported price of $129.9192 per share, with trade prices ranging from $129.45 to $130.23. This sale was made under a Rule 10b5-1 trading plan adopted on February 20, 2025, and she now directly holds 121,234 Gilead shares.

Gilead Sciences Chairman & CEO Daniel O'Day disclosed open-market sales of 15,000 shares of Common Stock. On July 1, 2026, he sold 3,100 shares at an average price of $127.075 and 11,900 shares at $126.0897, according to the Form 4.

The sales were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026, indicating they were pre-arranged rather than newly timed decisions. Footnotes state sale prices for the reported transactions ranged from $125.59 to $127.44, with full trade-by-trade details available on request.

Gilead Sciences executive Johanna Mercier reported open-market sales of 3,000 shares of Gilead common stock. The transactions occurred on June 15, 2026 at prices ranging from $122.79 to $125.40 per share, as described in the footnotes.

The filing states that these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. After the transactions, Mercier directly holds 124,234 shares of Gilead common stock, according to the reported post-transaction balance.

Gilead Sciences Chief Financial Officer sells shares under trading plan

Gilead Sciences CFO Andrew D. Dickinson reported an open-market sale of 3,000 shares of common stock at $125.40 per share. After the sale, he directly holds 171,646 shares. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Gilead Sciences Chief Medical Officer Dietmar Berger reported routine equity compensation activity. On June 10, 2026, he exercised 533 restricted stock units, converting them into the same number of Gilead common shares at an exercise price of $0.00 per share.

To cover associated tax obligations, 263 common shares were disposed of at $121.48 per share through a tax-withholding transaction, which is not an open-market sale. Following these transactions, he directly holds 19,252 shares of common stock and 46,928 restricted stock units, which continue to vest over a four-year schedule.

Gilead Sciences EVP and General Counsel Keeley M. Cain Wettan reported routine equity compensation activity. On June 10, 2026, 589 shares of common stock were acquired through a derivative exercise/conversion of restricted stock units at $0.00 per share.

On the same date, 283 shares of common stock were disposed of in a tax-withholding disposition at $121.48 per share to cover obligations tied to this equity event. After these transactions, the insider directly holds 5,360 shares of common stock and 19,997 restricted stock units, which vest over a four-year schedule.

Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported routine equity compensation activity. On June 10, 2026, he exercised restricted stock units covering 2,796 shares of common stock at a conversion price of $0.00 per share.

To cover tax obligations, 1,341 shares of common stock were disposed of as a tax-withholding transaction at $121.48 per share, rather than through an open-market sale. Following these transactions, he holds 174,646 shares of Gilead common stock directly and 27,851 restricted stock units, which vest over a four-year schedule.

Gilead Sciences, Inc. reported that Johanna Mercier, Chief Communications & Corporate Affairs Officer, exercised restricted stock units on June 10, 2026, converting 2,796 RSUs into the same number of common shares at a stated price of 0.00 per share. Each RSU represents the right to receive one share of common stock and follows a 4-year vesting schedule.

On the same date, 1,341 common shares were disposed of in a tax-withholding transaction at 121.48 per share. Following these transactions, she directly holds 127,234 shares of Gilead common stock and has 27,851 restricted stock units outstanding.

Gilead Sciences, Inc. Chairman & CEO Daniel Patrick O'Day reported the vesting and settlement of 8,779 restricted stock units into an equal number of common shares on June 10, 2026. In connection with this vesting, 4,213 shares of common stock were withheld at $121.4800 per share to satisfy tax obligations. Following these transactions, he directly held 622,133 shares of Gilead common stock, and 92,080 restricted stock units were reported as outstanding.

Gilead Sciences Chairman & CEO Daniel O'Day reported open-market sales of 15,000 shares of Common Stock. The trades took place on June 1, 2026 in three transactions at prices around $131 per share. Footnotes state these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 25, 2026, indicating the timing was scheduled in advance rather than discretionary.

Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported an open-market sale of 3,000 shares of common stock at an average price of $132.27 per share. After this transaction, he directly holds 173,191 shares of Gilead common stock. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, indicating the trade was scheduled in advance rather than timed discretionarily.

Gilead Sciences Chief Comm & Corp Aff Officer Johanna Mercier reported option exercises and share sales. On May 15, 2026, she exercised 25,000 non-qualified stock options at an exercise price of $66.64 per share and acquired the same number of common shares.

That day she also completed open-market sales totaling 28,000 shares of Gilead common stock in multiple trades at prices ranging from about $129.66 to $132.78 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, she directly holds 125,779 common shares and retains 23,110 stock options with a $66.64 exercise price expiring on July 24, 2029.

Gilead Sciences director Jeffrey Bluestone reported new equity awards. He received 1,146 restricted stock units under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, each representing one share of common stock, and the RSUs vested immediately on April 30, 2026. He was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, with 100% of the option vesting immediately on the same date. Following these transactions, he holds 10,066 shares of Gilead common stock directly, in addition to the option position.

Gilead Sciences director Jacqueline K. Barton received equity compensation on April 30, 2026. She was granted 1,146 restricted stock units that vested immediately, each representing one share of common stock, bringing her direct holdings to 27,202 shares. She also received a non-qualified stock option for 4,884 shares at an exercise price of $130.84 per share, with all option shares vesting immediately and expiring on April 30, 2036.

Gilead Sciences director Sandra Horning reported new equity compensation awards. She received 1,146 restricted stock units under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, with each RSU representing one share of common stock and vesting immediately on April 30, 2026.

She was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, which vested 100% on April 30, 2026 and expires on April 30, 2036. Following these awards, she directly holds 6,293 shares of Gilead common stock.

Gilead Sciences director Ted W. Love received new equity awards as part of his compensation. On April 30, 2026, he was granted 1,146 restricted stock units under the 2022 Equity Incentive Plan. Each RSU represents one share of common stock and vested immediately on the grant date.

On the same date, he was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, with all shares under the option vesting immediately and expiring on April 30, 2036. Following these awards, he directly holds 5,484 common shares and 4,884 options.

Gilead Sciences director Javier Rodriguez received new equity awards as part of his compensation. He was granted 1,146 restricted stock units, each representing one share of common stock, which vested immediately on April 30, 2026, raising his direct common stock holdings to 13,364 shares.

Rodriguez was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share. All of these option shares vested immediately on April 30, 2026 and are scheduled to remain exercisable until April 30, 2036.

Gilead Sciences director Anthony Welters reported equity awards rather than open-market trades. On April 30, 2026, he received 1,146 restricted stock units that each convert into one share of common stock and vested immediately. He was also granted 4,884 non-qualified stock options with a $130.84 exercise price, which fully vested on the grant date and are exercisable until April 30, 2036. Following the RSU grant, his direct common stock holdings totaled 12,894 shares.

Gilead Sciences director Harish Manwani reported routine equity compensation and related tax withholding. He received 1,146 restricted stock units, which vested immediately and increased his direct common stock holdings to 15,239 shares after the grant.

He also received a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, fully vested on April 30, 2026 and expiring in 2036. Separately, 224 shares were withheld at $130.84 per share to cover tax obligations, a non‑market, tax-withholding disposition rather than an open-market sale.

Gilead Sciences director Kelly A. Kramer received new equity awards as compensation. On April 30, 2026, Kramer was granted a non-qualified stock option covering 4,884 shares of Gilead common stock at an exercise price of $130.84 per share, expiring in 2036, with all shares vesting immediately on the grant date.

On the same date, Kramer also received 1,146 restricted stock units, each representing the right to receive one share of Gilead common stock. These RSUs vested 100% immediately at grant. Following the RSU award, Kramer’s reported RSU holdings totaled 20,256 units. These are awards from the company, not open‑market purchases.

Gilead Sciences Chairman & CEO Daniel O'Day sold 10,000 shares of common stock in open-market trades. The sales occurred on April 28, 2026 at prices around $128.79 and $130.01 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025. Following the sales, he continues to hold more than 600,000 shares of Gilead common stock directly.

Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson reported an open-market sale of company stock. On this Form 4, he sold 3,000 shares of Gilead Sciences common stock at a price of $140.96 per share.

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, indicating it was scheduled in advance. Following this sale, Dickinson continues to hold 176,191 shares of Gilead Sciences common stock directly.

Gilead Sciences, Inc. executive Johanna Mercier, Chief Commercial & Corporate Affairs Officer, sold 3,000 shares of common stock at $140.96 per share in an open-market transaction. After this sale, she directly holds 128,779 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025, indicating the timing was set in advance.

Gilead Sciences Chairman & CEO Daniel O'Day reported an open-market sale of 10,000 shares of Common Stock on 2026-03-27 at an average price of $136.8162 per share. The transaction was made under a Rule 10b5-1 trading plan adopted on 2025-02-28, with sale prices ranging from $136.51 to $137.22. Following this sale, he continues to directly hold 642,567 shares of Gilead Sciences common stock.

Gilead Sciences executive Johanna Mercier, Chief Commercial & Corporate Affairs Officer, sold 3,000 shares of Gilead common stock in an open‑market transaction at a price of $144.23 per share. After this sale, she directly holds 131,779 shares of Gilead common stock.

The filing notes that this transaction was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 20, 2025, indicating it was scheduled in advance rather than timed discretionarily.

Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock at $144.23 per share in an open-market transaction. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024. Following this trade, he directly holds 179,191 shares of Gilead common stock.

Gilead Sciences Chief Financial Officer Andrew Dickinson reported routine equity compensation activity. On March 10, 2026, he exercised restricted stock units into 6,469 shares of common stock and received a new grant of 9,590 restricted stock units, each representing one future share.

He was also granted 35,880 non-qualified stock options with an exercise price of $148.56 per share, expiring on March 10, 2036. Following the RSU exercise, 3,147 shares of common stock were withheld to cover tax obligations, leaving him with 182,191 common shares and 30,647 restricted stock units directly owned.

The RSU and option grants vest over four years, with 25% vesting on the first anniversary of the grant and the remaining 75% vesting in 6.25% quarterly installments, aligning his compensation with long-term shareholder value.

Gilead Sciences’ Chief Comm & Corp Aff Officer Johanna Mercier reported routine equity compensation activity. She exercised 6,617 restricted stock units into the same number of common shares, with 3,216 shares withheld at a price of 148.5600 per share to cover tax obligations, leaving her with 134,779 common shares held directly.

Mercier also received new awards: 9,590 restricted stock units and 35,880 non-qualified stock options exercisable at 148.5600 per share and expiring on March 10, 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting 6.25% quarterly.

Gilead Sciences EVP Keeley M Cain Wettan reported routine equity compensation changes. On March 10, 2026, 1,246 restricted stock units converted into the same number of common shares, increasing her direct common stock holdings to 5,054 shares after 606 shares were withheld to cover taxes.

She also received 5,050 new restricted stock units and 18,885 non-qualified stock options exercisable at $148.56 per share, expiring in 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting quarterly at 6.25% until fully vested.

Gilead Sciences SVP receives new equity awards. Senior Vice President of Controllership Erin Burkhart was granted 2,355 restricted stock units and 5,455 non-qualified stock options, each tied to Gilead common stock. Both awards have a four-year vesting schedule, with 25% vesting after one year and the remainder vesting quarterly. Following the grant, Burkhart directly holds 11,245 restricted stock units and 5,455 stock options with a $148.56 exercise price, providing long-term, performance-linked compensation rather than immediate market purchases or sales.

Gilead Sciences Chairman & CEO Daniel O'Day reported routine equity compensation changes. He exercised 20,026 restricted stock units into the same number of common shares, with 9,767 shares withheld to cover tax obligations, leaving him with 652,567 common shares held directly.

O'Day also received new equity awards: 32,815 restricted stock units and 122,755 non-qualified stock options exercisable at $148.56 per share and expiring on March 10, 2036. Both the RSUs and options vest over four years, with 25% vesting after one year and the remainder vesting 6.25% quarterly until fully vested.

Gilead Sciences Chief Medical Officer Dietmar Berger reported multiple equity compensation transactions. He exercised 2,133 restricted stock units into common shares, with 1,063 of those shares withheld at $148.56 per share to cover tax obligations rather than sold on the market.

Berger also received 8,415 new restricted stock units and a grant of 31,475 non-qualified stock options exercisable at $148.56 per share, expiring on March 10, 2036. Following these events, he directly holds 18,982 shares of common stock and 47,461 restricted stock units, all subject to multi-year vesting schedules.

Gilead Sciences Chief Financial Officer Andrew D. Dickinson acquired 11,090 shares of common stock through a grant/award on performance share units. These shares vested after both performance and service conditions were met, bringing his directly held total to 178,869 shares of Gilead common stock.